Arax Advisory Partners’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
KCM
SL
Arax Advisory Partners's CGEM Position: Q3 2026 in Review
Arax Advisory Partners reduced its Cullinan Therapeutics (CGEM) stake by 13% in Q3 2026, selling an estimated $6.57K and leaving 2,282 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.
Arax Advisory Partners first reported a position in CGEM in Q2 2024 and has held it in 7 quarters since. The position peaked at $47.8K in Q2 2026. 153 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Arax Advisory Partners held 2,282 shares of Cullinan Therapeutics worth $35K as of Q3 2026.
- Arax Advisory Partners sold 343 Cullinan Therapeutics shares in Q3 2026, an estimated $6.57K.
- Cullinan Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3614 holding.
- Arax Advisory Partners first reported a position in Cullinan Therapeutics in Q2 2024 and has held it in 7 quarters since.
- Arax Advisory Partners's Cullinan Therapeutics position peaked at $47.8K in Q2 2026.
- 153 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.